Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals, in collaboration with Servier Bio-Innovation LLC and Institut de Recherches Internationales Servier, is conducting a Phase 1b/2 study titled A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression. The study aims to evaluate the safety and efficacy of the anti-PD1 antibody, cemiplimab, in combination with other antibodies (S095018, S095024, or S095029) in patients with advanced NSCLC.
The study tests three experimental combinations: S095018, S095024, and S095029, each paired with cemiplimab. These combinations are intended to enhance the immune response against cancer cells in patients with high PD-L1 expression.
This interventional study follows a randomized, parallel assignment model with no masking. Its primary purpose is treatment, focusing on determining the recommended dose and assessing the efficacy of the combinations.
The study began on August 7, 2024, with its primary completion and estimated completion dates yet to be determined. The most recent update was submitted on August 4, 2025, indicating ongoing recruitment and progress.
The outcome of this study could significantly impact Regeneron’s market position, potentially boosting its stock performance if results are positive. It also positions Regeneron competitively within the immunotherapy sector, which is witnessing rapid advancements.
The study is currently ongoing, with further details available on the ClinicalTrials portal.